Medical Information
France
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you

This content is intended for French Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

Comirnaty COVID-19 mRNA vaccines (tozinameran)
(tozinameran / famtozinameran)

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

Comirnaty COVID-19 mRNA vaccines Quick Search

The last version of the Summary of Product Characteristics (SPC) for COMIRNATY forms can be accessed below:
Formulations for adults and adolescents ≥12 years:
  • 15/15 μg/dose tozinameran/ famtozinameran (Original/Omicron BA.4-5), ready-to-use, grey cap: SPC
  • 30 μg/dose tozinameran, ready-to-use, grey cap: SPC
  • 30 μg/dose tozinameran, dilution required, purple cap: SPC
Pediatric formulations:
  • For infants and children aged 6 months to 4 years: 3 μg/dose tozinameran, dilution required, maroon cap: SPC
  • For children aged 5 to 11 years: 10 μg/dose tozinameran, dilution required, orange cap: SPC
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event